YBX1 and neoplasm: Moreover, YBX1-dependent lysosomal adenovirus can synergize with CDK4/6 inhibitors to induce a reversal of tumor immunogenicity, resulting in heightened expression of HLA class I molecules, suppression of regulatory T cells, and augmentation of inflammatory anti-tumor responses, thereby enhancing local tumor control [119].